Karen L. Rigat

发表

Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus.

Carl T. Bergstrom, Chong-Hwan Chang, M. Witmer, 2011, Bioorganic & medicinal chemistry letters.

Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase.

A. Mathur, J. Cutrone, N. Meanwell, 2017, Bioorganic & medicinal chemistry letters.

Ligand-induced changes in hepatitis C virus NS5B polymerase structure.

B. Beno, M. Gao, Min Ding, 2010, Antiviral research.

A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase.

M. Gao, S. Roberts, Karen L. Rigat, 2006, Analytical biochemistry.

Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor.

N. Meanwell, J. Lemm, K. Yeung, 2017, ACS medicinal chemistry letters.

The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase.

B. Beno, K. Kish, S. Sheriff, 2017, MedChemComm.

The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase.

M. Poss, M. Gao, R. Fridell, 2011, Organic & biomolecular chemistry.

Development of a Cell-Based High-Throughput Specificity Screen Using a Hepatitis C Virus-Bovine Viral Diarrhea Virus Dual Replicon Assay

J. Lemm, R. Colonno, M. Gao, 2005, Antimicrobial Agents and Chemotherapy.

Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity

B. Kienzle, Lingling Jia, M. Gao, 2014, Antimicrobial Agents and Chemotherapy.

Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.

Chong-Hwan Chang, M. Witmer, B. Beno, 2014, Journal of medicinal chemistry.

Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.

B. Beno, M. Poss, J. Lemm, 2012, Bioorganic & medicinal chemistry letters.

Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

B. Beno, J. Marcinkeviciene, L. Abell, 2014, The Journal of Biological Chemistry.

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

N. Meanwell, J. Lemm, R. Colonno, 2014, Antimicrobial Agents and Chemotherapy.

De Novo Initiation of RNA Synthesis by the RNA-Dependent RNA Polymerase (NS5B) of Hepatitis C Virus

R. Hamatake, J. Lemm, G. Luo, 2000, Journal of Virology.

RNA template-mediated inhibition of hepatitis C virus RNA-dependent RNA polymerase activity.

M. Gao, Jin‐Hua Sun, S. Roberts, 2008, Archives of biochemistry and biophysics.

Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors.

M. Witmer, B. Beno, K. Kish, 2018, ACS medicinal chemistry letters.

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.

Qi Gao, Min Gao, Steven Sheriff, 2017, Journal of medicinal chemistry.

Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase.

N. Meanwell, J. Lemm, J. Kadow, 2016, Bioorganic & medicinal chemistry letters.

Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase.

M. Witmer, B. Beno, K. Kish, 2011, Bioorganic & medicinal chemistry letters.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

Min Gao, Nicholas A. Meanwell, Yong Tu, 2015, Nature.

The synthesis and evaluation of a novel class of (E)-3-(1-cyclohexyl-1H-pyrazol-3-yl)-2-methylacrylic acid hepatitis C virus polymerase NS5B inhibitors.

Carl T. Bergstrom, B. Beno, Scott W. Martin, 2011, Bioorganic & medicinal chemistry letters.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

N. Meanwell, D. Langley, J. Lemm, 2015, Nature.